Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study

Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study

Introduction: Immunization of patients with chronic lymphocytic leukemia (CLL) with vaccines against several infectious diseases has proven insufficient. Data on seroconversion of patients with CLL after vaccination against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) are still young...

Full description

Bibliographic Details
Main Authors: Panagiotis T. Diamantopoulos, Christos Stafylidis, Dimitra Vlachopoulou, Christina-Nefeli Kontandreopoulou, Nefeli Giannakopoulou, Maria Vardaka, Anthi Mpouhla, Elpida Mastrogianni, Eleni Variami, Athanasios Galanopoulos, Vasiliki Pappa, Mina Psichogiou, Angelos Hatzakis, Nora-Athina Viniou
Format: Article
Language:English
Published: SAGE Publishing 2022-05-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207221090150

Internet

https://doi.org/10.1177/20406207221090150

Similar Items